Focused On-demand Library for Succinate dehydrogenase assembly factor 1, mitochondrial

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
A6NFY7

UPID:
SDHF1_HUMAN

ALTERNATIVE NAMES:
LYR motif-containing protein 8

ALTERNATIVE UPACC:
A6NFY7; B2RPM7

BACKGROUND:
The protein Succinate dehydrogenase assembly factor 1, mitochondrial, also recognized as LYR motif-containing protein 8, plays a crucial role in the succinate dehydrogenase (SDH) enzyme complex assembly. This complex is essential for the TCA cycle and mitochondrial electron transport chain, linking succinate oxidation with ubiquinone reduction. It promotes SDHB subunit maturation, protecting against oxidative stress, and facilitates iron-sulfur cluster integration into SDHB.

THERAPEUTIC SIGNIFICANCE:
Linked to Mitochondrial complex II deficiency, nuclear type 2, this protein's dysfunction can lead to a spectrum of clinical outcomes, from infant mortality to adult-onset cardiac or muscle issues. Exploring the function of Succinate dehydrogenase assembly factor 1 could unveil novel therapeutic avenues, potentially revolutionizing treatment approaches for mitochondrial diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1062 of 8789